Debrichem
® offers a very effective, alternative approach to chronic wound care, initiating healing in more than 90 % of cases after one application
1
Chronic wounds affect 1 – 2 % of developed countries’ populations,
2 unsuccessful treatment may lead to enlargement of the wound, bone involvement or in the worst case, amputation
3
ROTTERDAM, The Netherlands, Feb. 25, 2021 (GLOBE NEWSWIRE) DEB
x Medical, the Dutch medical technology company revolutionizing the management of chronic wounds, is excited to highlight today the successful completion of the CE conformity assessment procedure for Debrichem
®. The innovative topical agent offers a superior alternative to surgical debridement, the current standard of care. Debrichem can now carry the CE mark for a medical device class IIb and has also been awarded ISO 13485:2016 certification. These certifications endorse the quality and safety of Debrichem to treat a high unmet medical need and the strength of the DEB